| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
313.95(M) |
| Last
Volume: |
1,560,200 |
Avg
Vol: |
2,306,261 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
92,653 |
92,653 |
204,995 |
510,803 |
| Total Sell Value |
$124,554 |
$124,554 |
$194,453 |
$1,231,647 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
4 |
13 |
34 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Robin Howard W |
President & CEO |
• • – |
2019-02-21 |
4 |
OE |
$7.21 |
$240,331 |
D/D |
33,333 |
342,042 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2019-02-20 |
4 |
AS |
$43.20 |
$1,440,029 |
D/D |
(33,334) |
308,709 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2019-02-20 |
4 |
OE |
$7.21 |
$240,338 |
D/D |
33,334 |
342,043 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2019-02-19 |
4 |
S |
$42.39 |
$101,143 |
D/D |
(2,386) |
97,143 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2019-02-19 |
4 |
S |
$42.39 |
$152,265 |
D/D |
(3,592) |
131,702 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2019-02-19 |
4 |
S |
$42.39 |
$140,311 |
D/D |
(3,310) |
99,374 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2019-02-19 |
4 |
S |
$42.39 |
$162,015 |
D/D |
(3,822) |
170,655 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2019-02-19 |
4 |
S |
$42.39 |
$76,641 |
D/D |
(1,808) |
166,391 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2019-02-19 |
4 |
AS |
$42.32 |
$1,787,161 |
D/D |
(42,215) |
308,709 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2019-02-19 |
4 |
OE |
$7.21 |
$240,331 |
D/D |
33,333 |
350,924 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2019-02-04 |
4 |
AS |
$42.16 |
$679,577 |
D/D |
(16,119) |
168,199 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2019-02-04 |
4 |
OE |
$10.69 |
$172,312 |
D/D |
16,119 |
184,318 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2019-01-28 |
4 |
AS |
$42.82 |
$2,697,660 |
D/D |
(63,000) |
174,477 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2019-01-28 |
4 |
OE |
$10.69 |
$673,470 |
D/D |
63,000 |
237,477 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
68,450 |
317,591 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
23,950 |
102,684 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
10,950 |
168,199 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
18,500 |
99,529 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2018-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
28,750 |
135,294 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2018-11-16 |
4 |
S |
$38.25 |
$249,199 |
D/D |
(6,515) |
106,544 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2018-11-16 |
4 |
S |
$38.25 |
$173,043 |
D/D |
(4,524) |
78,734 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2018-11-16 |
4 |
S |
$38.25 |
$228,812 |
D/D |
(5,982) |
174,477 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-11-16 |
4 |
S |
$38.25 |
$586,220 |
D/D |
(15,326) |
249,141 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2018-11-16 |
4 |
S |
$38.25 |
$179,546 |
D/D |
(4,694) |
81,029 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2018-11-16 |
4 |
S |
$38.25 |
$153,612 |
D/D |
(4,016) |
157,249 |
|
- |
|
913 Records found
|
|
Page 12 of 37 |
|
|
